Entacapone for Parkinson’s Disease (Comtess)
Entacapone enhances levodopa effectiveness in Parkinson's, reducing 'wearing-off' symptoms for better symptom control.
Entacapone, marketed as Comtess, is a medication specifically designed to enhance the effects of levodopa in patients with Parkinson’s disease who experience end-of-dose deterioration or ‘wearing-off’ symptoms. It acts as a selective catechol-O-methyltransferase (COMT) inhibitor, prolonging levodopa’s action by preventing its peripheral breakdown, thereby increasing dopamine availability in the brain.
About entacapone
Parkinson’s disease is a progressive neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the substantia nigra, leading to motor symptoms such as tremor, rigidity, bradykinesia, and postural instability. Levodopa, often combined with carbidopa (as co-careldopa or co-beneldopa), remains the gold standard for symptomatic treatment, as it crosses the blood-brain barrier and converts to dopamine.
However, with disease progression, patients often develop motor fluctuations, including the ‘wearing-off’ phenomenon where symptom control diminishes before the next dose. Entacapone addresses this by inhibiting COMT, an enzyme that metabolizes levodopa in peripheral tissues, thus extending its plasma half-life by up to 75% and increasing brain dopamine levels for more consistent symptom relief.
Unlike tolcapone, entacapone does not cross the blood-brain barrier significantly and is not associated with hepatotoxicity, making it safer for long-term use. Clinical trials demonstrate that adding entacapone (200 mg with each levodopa dose) increases ‘on’ time by about 1.3 hours daily while reducing ‘off’ time, improving Unified Parkinson’s Disease Rating Scale (UPDRS) scores in activities of daily living and motor function.
Before taking entacapone
Allergies
Do not take entacapone if you have a known hypersensitivity to entacapone, levodopa, carbidopa, or any excipients in the formulation. Rare allergic reactions include rash, urticaria, or anaphylaxis.
Other medical conditions
- Liver disease: Entacapone is contraindicated in severe hepatic impairment due to reduced clearance; use cautiously in mild to moderate cases with dose adjustment.
- Psychiatric disorders: May exacerbate psychosis, hallucinations, or depression; monitor closely.
- Cardiovascular disease: Orthostatic hypotension risk increases; avoid in narrow-angle glaucoma or pheochromocytoma.
- Gastrointestinal issues: History of ulcers or bleeding requires caution due to potential diarrhea.
- Pregnancy and breastfeeding: Limited data; use only if benefits outweigh risks. Not recommended during breastfeeding.
Other medicines
Entacapone interacts with several drugs:
| Drug Class | Examples | Interaction |
|---|---|---|
| MAO-B inhibitors | Selegiline, rasagiline | Increased levodopa effects; monitor for dyskinesia. |
| Non-selective MAO inhibitors | Phenelzine | Contraindicated; risk of hypertensive crisis. |
| Iron supplements | Ferrous sulfate | Reduces entacapone absorption; separate by 2-3 hours. |
| Antipsychotics | Haloperidol | Antagonizes dopamine effects; avoid. |
| Probencid | – | Increases entacapone levels; dose reduction may be needed. |
Always inform your doctor of all medications, including over-the-counter and herbal supplements.
How and when to take entacapone
Entacapone is taken orally as 200 mg tablets with each dose of levodopa/carbidopa (up to 10 times daily, maximum 2000 mg/day). Swallow whole with or without food; food may delay absorption but not efficacy.
- Starting dose: 200 mg per levodopa dose.
- Adjustments: Titrate based on response; discontinue if no benefit after 2-3 weeks.
- Missed dose: Take as soon as remembered unless near next dose; do not double up.
- Combination products: Available as levodopa/carbidopa/entacapone (e.g., Stalevo) for convenience.
For advanced patients, levodopa-entacapone-carbidopa intestinal gel (LECIG) infusion provides continuous delivery.
Dosage
Standard adult dose: 200 mg with every levodopa/carbidopa dose (typically 4-10 times/day). In trials, this regimen significantly improved ‘on’ time without increasing levodopa dose. Elderly or renally impaired: No adjustment needed, but monitor.
Getting the most from your treatment
- Take exactly as prescribed to avoid fluctuations.
- Maintain consistent timing with levodopa doses.
- Monitor symptoms with a diary to track ‘on’/’off’ times.
- Combine with physical therapy, exercise, and speech therapy for holistic management.
- Avoid high-protein meals near doses, as they compete with levodopa absorption.
- Regular follow-ups to adjust therapy as Parkinson’s progresses.
Side effects
Common side effects (affecting >1 in 10):
- Abnormal movements (dyskinesia) – may require levodopa dose reduction.
- Diarrhea (often resolves in weeks).
- Urine discoloration (orange-brown, harmless).
- Nausea, abdominal pain.
Serious side effects (rare):
- Hallucinations, confusion (especially elderly).
- Orthostatic hypotension.
- Rhabdomyolysis (monitor CK if persistent symptoms).
- Impulse control disorders (gambling, hypersexuality).
Report persistent diarrhea (>3 days), severe dyskinesia, or mental changes immediately.
Pregnancy and breastfeeding
Entacapone is category C in pregnancy; animal studies show no teratogenicity, but human data limited. Use only if essential. Excreted in milk; avoid breastfeeding.
Other precautions
- Driving/operating machinery: May cause somnolence or sudden sleep onset; assess fitness to drive.
- Diet: No specific restrictions, but optimize protein intake.
- Monitoring: Liver function, blood counts periodically; watch for melanoma risk with levodopa.
- Overdose: Symptoms include agitation, hyperkinesia; seek emergency care.
Common questions
How long does entacapone take to work? Effects noticeable within days, full benefit in 2-4 weeks.
Can I stop suddenly? Taper to avoid worsening symptoms; consult doctor.
Does it cure Parkinson’s? No, symptomatic only; does not slow progression.
Frequently Asked Questions (FAQs)
Q: Who should take entacapone?
A: Patients with Parkinson’s experiencing ‘wearing-off’ on levodopa/carbidopa, prescribed by specialists.
Q: What if I experience dyskinesia?
A: Reduce levodopa dose by 10-30%; consult your neurologist.
Q: Is entacapone safe long-term?
A: Yes, well-tolerated in trials up to 1 year; monitor for side effects.
Q: Can it be used alone?
A: No, always adjunct to levodopa/carbidopa.
Q: How does it differ from opicapone?
A: Opicapone is longer-acting (once daily); entacapone requires multiple doses.
References
- Entacapone. A review of its use in Parkinson’s disease — Drugs. 1999-08-01. https://pubmed.ncbi.nlm.nih.gov/10439935/
- Levodopa/Carbidopa/Entacapone Combination Therapy — StatPearls [Internet]. 2023. https://www.ncbi.nlm.nih.gov/books/NBK599508/
- Entacapone: Uses, Interactions, Mechanism of Action — DrugBank Online. 2023. https://go.drugbank.com/drugs/DB00494
- Entacapone: MedlinePlus Drug Information — MedlinePlus. 2023-05-15. https://medlineplus.gov/druginfo/meds/a601236.html
- Entacapone for Parkinson’s disease – Patient.info — Patient.info. 2023. https://patient.info/medicine/entacapone-for-parkinsons-disease-comtess
- COMT inhibitors (entacapone, tolcapone, opicapone) — Parkinson’s UK. 2023. https://www.parkinsons.org.uk/information/drugs/comt-inhibitors
Similar Articles
Read full bio of medha deb
